Ariel Hurley Sells 1,819 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Ariel Hurley sold 1,819 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $93.26, for a total transaction of $169,639.94. Following the sale, the insider now owns 14,967 shares of the company’s stock, valued at $1,395,822.42. The trade was a 10.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Blueprint Medicines Stock Up 1.1 %

BPMC stock opened at $96.48 on Wednesday. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27. The company has a 50-day moving average of $92.33 and a two-hundred day moving average of $97.32. The stock has a market capitalization of $6.13 billion, a price-to-earnings ratio of -45.73 and a beta of 0.59. Blueprint Medicines Co. has a 52-week low of $72.24 and a 52-week high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The company had revenue of $128.20 million for the quarter, compared to the consensus estimate of $127.56 million. During the same period in the previous year, the business posted ($2.20) EPS. The company’s revenue for the quarter was up 126.5% on a year-over-year basis. As a group, equities research analysts anticipate that Blueprint Medicines Co. will post -3.68 EPS for the current year.

Hedge Funds Weigh In On Blueprint Medicines

Several large investors have recently bought and sold shares of the stock. Quarry LP bought a new position in shares of Blueprint Medicines during the 3rd quarter worth about $32,000. Covestor Ltd increased its stake in Blueprint Medicines by 206.7% during the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 403 shares during the period. Quantbot Technologies LP acquired a new position in Blueprint Medicines in the 3rd quarter valued at approximately $108,000. CWM LLC lifted its position in shares of Blueprint Medicines by 114.6% in the 2nd quarter. CWM LLC now owns 1,105 shares of the biotechnology company’s stock worth $119,000 after acquiring an additional 590 shares during the period. Finally, Van ECK Associates Corp lifted its position in shares of Blueprint Medicines by 13.3% in the 2nd quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $120,000 after acquiring an additional 131 shares during the period.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on BPMC shares. StockNews.com upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. UBS Group began coverage on shares of Blueprint Medicines in a report on Thursday, October 24th. They issued a “neutral” rating and a $88.00 target price for the company. Guggenheim restated a “buy” rating on shares of Blueprint Medicines in a report on Wednesday, December 11th. Wedbush reaffirmed an “outperform” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research note on Thursday, November 14th. Finally, Wells Fargo & Company cut their target price on shares of Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Blueprint Medicines currently has a consensus rating of “Moderate Buy” and a consensus price target of $122.11.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.